TheracosBio’s oral sodium-glucose cotransporter 2 inhibitor Brenzavvy, or bexagliflozin, has gained FDA approval as an adjunct to exercise and diet for improving glycemic control in type 2 diabetes patients. The approval was supported by data from 23 clinical trials with more than 5,000 participants.
Full Story: eMPR (1/23)